Time Pharmaceuticals IPO: Is Nepal's New Pharma Listing Worth NPR 450?

01 · The Business

Thirty years on the factory floor, one on the roadshow circuit

Founded in 1995, Time Pharmaceuticals continues to operate from the same industrial address in Gaindakot. Commercial production started in November 1997, and the firm received the WHO-GMP certification in 2005. Three decades later, it is one of only a handful of Nepali pharmaceutical manufacturers, as opposed to importers or distributors, trying to list on NEPSE. This makes this a less directly comparable listing than the usual hydropower or microfinance debut, and one that is scarcer than most.

At a glance
Founded / Commercial production	1995 / Nov 1997
WHO-GMP certified	Since 2005
Manufacturing site	Gaindakot-10, Nawalpur
Product portfolio	200+ SKUs
Manufacturing blocks	4 (Penicillin, Cephalosporin, Sterile, Non-Pen)
Dosage forms	Tablets, capsules, liquids, topicals, drops
ICRA Nepal issuer rating	[ICRANP-IR] BBB-
Shares outstanding pre-issue	4,213,500
Shares outstanding post-issue	5,300,000

It produces more than 200 formulations in tablets, capsules, oral liquids, and topical preparations, sold through some nine internal sales divisions which together carry brand families including Sinex (its largest consumer franchise, a cold-and-flu line), Paraflam, Salif, Pulmarin, Empath, Ursobyl, and the Himox/Montime lines. Its own account puts headcount above 1,000 across the full commercial organization; independent reporting around the IPO more conservatively cites roughly 300 staff at the Gaindakot manufacturing site itself. The gap is most likely the nationwide field force of medical representatives running the nine sales divisions, rather than a discrepancy worth worrying about.

Manufacturing is carried out in four purpose-built blocks, each with its own independent air handling system. Penicillin, Cephalosporin, Sterile (eye/ear/nasal drops), and non-penicillin general formulations covering cardiovascular, antidiabetic, CNS, gastrointestinal, dermatology, and nutrition products. Segregation is a genuine regulatory requirement for β-lactam manufacturing, not a marketing flourish. WHO-GMP certification across the site is a real quality signal in a domestic industry where it is not universal.

The core pharma business is supported by two small non-core investments, a 100% subsidiary in nutraceuticals, Time Lifestyle Pvt. Ltd. (import and marketing of dietary supplements with manufacturing plans), and a 10.77% stake in Time Pharma Investment Pvt. Ltd. Total assets of NPR 1.54 billion vs combined book value of both less than NPR 17 million – interesting optionality, immaterial to valuation.

02 · The Industry

A fragmented market that imports more than it makes

Nepal’s domestic drug manufacturers have provided a remarkably stable and remarkably low share of the country’s own medicine consumption for two decades: around 41-45%, with the remaining majority imported, mainly from India, but increasingly from China and Bangladesh. That ceiling has not moved much despite a rise in the number of local manufacturers, which is the central tension of the industry: more factories chasing a domestic share that is not growing to meet them.

Two structural forces explain the ceiling. First, government procurement and pricing policy have historically favored cheaper imports over protection for domestic manufacturing, a complaint made explicitly and repeatedly by the Association of Pharmaceutical Producers of Nepal (APPON), whose previous leadership has argued that the sector could substitute far more imports if policy incentives were equal to those given to, say, cement or noodles. Second, it is truly fragmented: there are 50+ active manufacturers competing for that ~41-45% domestic pool, and importers carry the product lines of about 390 foreign manufacturers. Entry barriers are low, and pricing pressure is constant. ICRA Nepal’s own sector commentary on similar domestic manufacturers points out precisely this combination: a ‘fragmented market, low entry barriers and exposure to cheaper imports’ as a structural, industry-wide rating constraint, not a company-specific flaw.

Nepal pharmaceutical market
Domestic manufacturing share of consumption	~41–45%
Imported share	~55–59%
Primary import source	India, then China, Bangladesh
Active domestic manufacturers	50+
API import dependency	~70% India / ~30% China
Regulator	Dept. of Drug Administration

The raw material supply adds to the exposure: Nepali formulators import about 70% of active pharmaceutical ingredients from India and 30% from China, so margins carry currency and cross-border logistics risk on the input side even when the finished product never crosses a border.  None of this is unique to Time Pharma; it is the operating environment that all domestic manufacturers.

03 · The Track Record

Revenue that hasn't grown in four years, but profit that's learned to work harder

Particulars (In Million)	2079	2080	2081	2082	2082-83 (Q3)
Revenue	990.16	822.13	956.07	904.11	671.19
Revenue Growth		-16.97%	16.29%	-5.44%
Gross Margin (%)	48.03%	49.68%	51.84%	51.76%	50.00%
EBITDA Margin (%)	17.60%	17.50%	18.59%	18.88%	15.46%
Net Profit	72.69	35.72	71.57	76.47	43.10
Net Margin (%)	7.34%	4.34%	7.49%	8.46%	6.42%
EPS	34.89	15.58	19.61	20.95	10.23

The uncomfortable number first: revenue in FY2082 (NPR 904 million) was lower than in FY2079 (NPR 990 million), four years earlier. In fact, the three-year CAGR in revenues to FY2082 is negative at about −3.0% per annum, with a steep COVID-hangover drop-off in FY2080 and partial recovery since. Margins, however, have been steadily improving, gross margin moving up from 48.0% to a steady ~51–52% and net margin rising from a rough 4.3% trough in FY2080 to 8.5% in FY2082. This is a company that has gotten better at running the business it has, without expanding that business, yet.

What the margin lines tell you: the rise in gross margin from 48% to ~52% is mostly procurement and product-mix discipline, the kind of believable, durable improvement you get from a manufacturer. EBITDA margin has been in a tighter range (17.5%–18.9%) as selling and employee costs have risen with it. The difference between EBITDA margin and net margin is finance cost, funding the working capital, which is why net margin fell hardest exactly when finance costs spiked in FY2080 (Nepal's system-wide lending rates were also near their multi-year peak that year; see the WACC build in Section 6).

04 · What Drives the Business

One brand drives sales, but capital is working harder for lower returns

Nine internal sales divisions carry the brand portfolio, and while concentration is real, it’s not alarming: the Time Sales division alone, home to Sinex and other flagship lines, accounts for roughly a quarter of revenue, with Cosmo, Genesis, Nexus, and Erra contributing a further 13-18% each. The top three divisions make up just under 57% of sales. That’s a diversified-enough spread that no single product recall or distributor dispute would be existential, but the concentration in the top division is something to watch as a single point of brand-reputation exposure.

Job work income, a contract/toll manufacturing for third parties, has grown from nothing in FY2080 to 8.1% of revenue in FY2082, a useful swing capacity utilizer for a plant that otherwise has fixed manufacturing overhead regardless of in-house volume.

Return on equity is declining, and dilution explains much of it.

The declining trend of shareholder returns can be explained using the DuPont identity – ROE = Net Profit Margin × Asset Turnover × Equity Multiplier. Profit margins have steadily improved over the last three full fiscal years, rising from 4.3% to 7.5% and then 8.5%, reflecting stronger profitability. However, asset turnover has collapsed from 0.83× to 0.87×, then 0.64×, then 0.44× (based on the latest nine-month non-annualized figures). This implies that the growth of assets, particularly working capital and the revaluation of property in FY2082, has been much faster than that of revenue.

The equity multiplier simultaneously kept decreasing from 2.62× to 1.92× and then 1.77× and 1.82×, indicating that the company has been funding growth by using new equity instead of new debt. This lowers financial risk, but it also lowers the leverage that can boost returns on equity.

	2079	2080	2081	2082	2082-83 (Q3)
Net Profit Margin	7.3%	4.3%	7.5%	8.5%	6.4%
Asset Turnover	1.05x	0.83x	0.87x	0.64x	0.44x
Equity Multiplier	2.57x	2.62x	1.92x	1.77x	1.82x
= Return on Equity	19.85%	9.40%	12.43%	9.67%	5.10%

It’s a mixed picture. Higher profit margins are encouraging, and lower leverage strengthens the balance sheet, but weaker asset utilization has far outweighed those positives. ROE thus touched a high of 14.97% in FY2081 and then fell to around 7% on an annualized basis in the current fiscal. The IPO will increase the share count by another 20.5% and add to the equity base that is likely to keep ROE under pressure until the new capital is deployed efficiently enough to generate higher sales growth.

Who owns it?

Time Pharma is a privately held pre-IPO company where the top ten shareholders control 57% of the register, led by Alpha Capital Limited (14.5%) and individual promoter-linked holders Raju Karmacharya (9.0%) and Jhamka Nath Bhatta (8.5%). The rest, 43%, is divided among about 165 other holders. Share capital has nearly doubled since FY2079 – from 2.08 million to 4.21 million shares pre-issue – through a mix of bonus capitalization and at least one premium-priced private placement to institutional investors (reportedly at around NPR 375/share), consistent with a company preparing its cap table for a public listing.

The 1,086,500 new shares will dilute existing holders by 20.5% post-issue, and public shareholders will own that same 20.5% outright, a normal, unremarkable dilution profile for a book-built IPO of this size.

05 · Relative Valuation

Against its listed manufacturing peers, this offer looks almost conservative

We cannot find a pure-play listed pharma manufacturer in Nepal to benchmark against, so the set here is the wider NEPSE "Manufacturing and Processing" index containing sixteen names, ranging from bottlers, cement, cables, distilleries, and consumer goods, using Time Pharma's own reference price of NPR 500 (QIIs' cut-off guidance figure, as no market LTP exists yet). It’s an imperfect peer set, but it’s the peer set the market itself uses to price this sector, and the read is telling.

Time Pharma would trade at 2.49x book value at its NPR 500 reference, below the 16-name peer median of 4.40x and below all but three of its comparables. On a P/E basis, the picture is less clear. The EPS number reported by Time Pharma in this model is a nine-month non-annualized number (NPR 10.23). Straight-lined annualized (x4/3) to NPR 13.64, the stock’s P/E at NPR 500 works out to a rough 48x versus a peer median of 41.77x, essentially in line, not stretched. Three peers (GCIL, OMPL, and SAGAR) are excluded from that median entirely because they are currently loss-making.

Relative valuation, worked through
Peer median P/E (excl. loss-makers)	48.88x
Peer median P/B	4.40x
× TIME EPS (9M, unannualized)	NPR 427.3
× TIME book value/share	NPR 881.09
Blended average (unannualized EPS)	NPR 654.21

Based on a mix of both multiples against Time Pharma’s own fundamentals and peer pricing points, it’s somewhere in the NPR 420-890 range, depending on which multiple you lean on, averaging to roughly NPR 655, which is not coincidentally close to what the company’s own prospectus valuation landed on (NPR 666.78). The market multiple case for this listing is as follows: considering the way NEPSE is pricing similar manufacturers currently, the announced QII cut-off (500) and, even more so, the projected public price (450) appear to be discounted, rather than at a premium.

06 · Intrinsic Value

The cash-flow case: NPR 286 to NPR 317, depending on how kindly you model growth

Strip out the multiples and the roadshows and ask the oldest question in the game: what's the discounted value of the cash this business is actually going to throw off? The model below, run as a typical eight-year (till 2090 BS) FCFF-to-equity bridge, revenue growth, historical cost ratios, a WACC built up from first principles, and a GDP-anchored terminal growth rate, yields a base-case intrinsic value of NPR 308.83 per share, with a bear-to-bull range of NPR 286 to NPR 317.

DCF scenario assumptions
Revenue growth p.a. (bear/base/bull)	4% / 5% / 6%
COGS (all scenarios)	48.5% of revenue
CAPEX (all scenarios)	3.2% of revenue
Explicit forecast window	FY2083 – FY2090 (8 yrs)
Terminal growth rate	4.15% (avg. GDP growth since FY2006/07)
WACC	10.31%
Cost of equity (CAPM)	11.94%
Adj. Levered beta	1.042
After-tax cost of debt	7.82%
Equity: debt weights	60.4%: 39.6%

Where the model is deliberately conservative:

Assumption of 4-6% annual revenue growth on a ‘same business, same footprint’ basis. It does not credit the plant expansion that this IPO is partly funding, or any market share gain of being the newly visible, newly capitalized name in a fragmented field. If the expansion capex materially lifts volume, the true intrinsic value is above this range.

Where it isn't

A WACC of 10.31% and a GDP-linked terminal growth rate of 4.15% are both defensible, unaggressive choices for a Nepali industrial issuer – not numbers created to justify a low answer. The COGS ratio and CAPEX intensity of this company are based on its own multi-year historical average, not an optimistic external benchmark.

The cash flows, year by year: Base Case

All the numbers above are endpoints. This is the walk to get you there. 8 years of revenue building to EBITDA taxed at a model's effective 20% on EBIT adjusted for capex and working capital discounted back at 10.31%. Valuation at Q3 FY2082/83 implies the first forecast year is a 0.25-year stub (only three months left in FY2083). Each subsequent year discounts a full 12 months further out.

	FY83	FY84	FY85	FY86	FY87	FY88	FY89	FY90
Revenue	949.3	996.8	1,046.6	1,098.9	1,153.9	1,211.6	1,272.2	1,335.8
EBITDA	190.7	200.2	210.2	220.7	231.8	243.3	255.5	268.3
EBITDA margin	20.1%	20.1%	20.1%	20.1%	20.1%	20.1%	20.1%	20.1%
−Depreciation & amortization	33.2	34.9	36.6	38.5	40.4	42.4	44.5	46.8
= EBIT	157.4	165.3	173.6	182.3	191.4	200.9	211.0	221.5
− Tax on EBIT @ 20%	31.5	33.1	34.7	36.5	38.3	40.2	42.2	44.3
NOPAT	126	132.3	138.9	145.8	153.1	160.8	168.8	177.2
+ D&A added back	33.2	34.9	36.6	38.5	40.4	42.4	44.5	46.8
− CAPEX (3.2% of revenue)	30.4	31.9	33.5	35.2	36.9	38.8	40.7	42.7
± Net working capital movement	+55.4	-76.1	-42.6	-38.2	-25.2	-52.6	-44.7	-45.1
= FCFF	184.2	59.2	99.4	110.9	131.4	111.8	127.9	136.1
Discount period (years)	0.25	1.25	2.25	3.25	4.25	5.25	6.25	7.25
Discount factor @ 10.31%	0.976	0.885	0.802	0.727	0.659	0.598	0.542	0.491
PV of FCFF	179.7	52.3	79.7	80.6	86.6	66.8	69.3	66.8

All figures are in millions of NPR, except margins, periods, and discount factors. Σ PV of FCFF = 681.96m, as per the bridge table below. Notice how volatile the working-capital line is year to year, this is a model's own forward projection of the same DSO/DIO/DPO dynamics documented historically in Section 6, and it is the single biggest swing factor in FCFF from one year to the next: FY84's cash flow is less than a third of FY83's almost entirely because of an NPR 76m working-capital build the model assumes that year.

Why Tax is 20%, not 25%?

The above operating cash flows are taxed at an effective rate of 20% on EBIT, which is the reduced corporate tax rate for manufacturing companies in Nepal. That’s a different number than the 25% effective rate used later, which is solely used for the after-tax cost of debt within the WACC calculation; the two serve different purposes in the model (operating tax vs. a financing-side input), and both are defensible on their own terms, but it’s worth knowing they aren’t the same number if you rebuild any of this yourself.

How much does this move if the two big assumptions shift?

WACC and terminal growth are the two inputs every DCF lives or dies by, and both involve real judgment calls. Keeping the base-case operating assumptions static and varying only these two – one point in either direction on each show how much of the NPR 309 headline truly is load-bearing.

WACC ↓ / Terminal growth →	3.15%	3.65%	4.15%	4.65%	5.15%
9.31%	329.24	355.85	387.62	426.21	474.10
9.81%	296.90	318.88	344.74	375.61	413.12
10.31%(base)	269.10	287.47	308.83	333.97	363.98
10.81%	244.94	260.47	278.33	299.10	323.53
11.31%	223.76	237.01	252.11	269.47	289.66

Intrinsic value per share (NPR) with base-case FCFF held constant and only the discount rate and terminal growth rate being adjusted. Highlighted cell is headlining base case (WACC 10.31%, terminal growth 4.15%)

The honest takeaway from this grid

The intrinsic value on both inputs across the reasonable ±1 point band is between NPR 224 and NPR 474, a wider range than the bear-to-bull operating range shown in the above chart. A one-point WACC swing alone moves the answer by approximately NPR 35–55 per share. This is not a flaw of this specific model; it is the nature of terminal-value-heavy DCFs where, as is the case here, the terminal value is worth roughly 1.6-1.7x the entire explicit eight-year forecast period combined.

Where does this leave the public price?

Even in the most optimistic corner of this grid, a 9.31% WACC and 5.15% terminal growth, both meaningfully more optimistic than a model's own inputs, intrinsic value tops out at NPR 474, still below the expected NPR 500 QII cut-off. To justify the institutional price just on cash flows, you would have to move both inputs at the same time past what this note thinks is a defensible range. That is the clearest evidence in this entire note that the bid is being driven by multiple-based sentiment and not discounted cash flow.

	BEAR	BASE	BULL
Terminal value (undiscounted)	2,135.5m	2,303.0m	2,375.2m
PV of terminal value	1,048.7m	1,131.1m	1,166.5m
Σ PV of explicit FCFF (8 yrs)	668.0m	682.0m	681.6m
Enterprise value	1,716.7m	1,813.0m	1,848.1m
− Total debt (Q3 FY2082/83)	(554.6m)	(554.6m)	(554.6m)
+ Cash & investments	42.8m	42.8m	42.8m
Equity value	1,205.0m	1,301.3m	1,336.4m
÷ Shares outstanding (pre-issue)	4,213,500	4,213,500	4,213,500
Intrinsic value per share	NPR 285.98	NPR 308.83	NPR 317.16

Equity bridge uses the pre-issue share count in accordance with this being the intrinsic value of the business that investors are buying into before the new capital/new shares from this offer are added. All figures in NPR unless otherwise indicated.

07 · Conclusion

Final Valuation Assessment

Looking at Time Pharma through two different valuation lenses leads to two very different conclusions. The company’s intrinsic value, using discounted cash flow (DCF) analysis, which values the business on the cash it is expected to generate, is in a relatively narrow range of NPR 286–317 per share, with a base-case estimate of NPR 304. Even on a more optimistic assumption base (lower discount rate and higher terminal growth), the valuation rises only to about NPR 474, still below the price the company is proposing for its public issue.

The picture is significantly different when the firm is valued using market multiples. Using the valuation levels currently given to comparable manufacturing companies listed on NEPSE, we arrive at an estimated range of NPR 420–890 per share, with an average of approximately NPR 654. This is remarkably close to Time Pharma’s own prospectus valuation of NPR 666.78, suggesting that the offering price is largely aligned with prevailing market sentiment rather than the company’s current cash-generating ability.

The important thing to understand is not that one valuation is right and the other wrong, but that they answer different questions. The DCF shows what Time Pharma’s current operations can justify based on current fundamentals, while the market multiple approach shows what investors are willing to pay for a rare listed pharmaceutical manufacturer in Nepal. The difference of about NPR 350 per share between the two approaches is a reflection of the premium the market is giving to future growth expectations.

Whether that premium ultimately proves justified will depend on one critical factor: execution. If the capital raised through the IPO successfully expands production capacity and translates into meaningful revenue growth after several years of relatively flat performance, the company's intrinsic value could gradually converge toward the valuation currently implied by the market. If that growth fails to materialize, however, the valuation premium may prove difficult to sustain.

Disclaimer

This report has been prepared solely for informational and educational purposes and does not constitute investment advice, an offer to buy or sell securities, or a recommendation to participate in the Initial Public Offering (IPO) of Time Pharmaceuticals Limited. The analysis, financial projections, and valuation estimates presented herein are based on publicly available information, including the company's prospectus, audited financial statements, regulatory disclosures, and other sources believed to be reliable. However, no representation or warranty is made regarding the accuracy, completeness, or timeliness of such information.

The valuation presented in this report is subject to numerous assumptions, including projected financial performance, discount rates, terminal growth rates, market conditions, and comparable company multiples. Actual results may differ materially from those projected due to changes in economic conditions, industry dynamics, regulatory developments, company-specific factors, or other unforeseen events.

The views and opinions expressed are those of the author as of the date of publication and are subject to change without notice. Investors should conduct their own independent research, carefully review the official prospectus, and consult with qualified financial, legal, or tax advisors before making any investment decisions.

The author shall not be held liable for any direct or indirect loss or damage arising from the use of this report or reliance on its contents.

Disclosure: The author does not receive any compensation from Time Pharmaceuticals Limited, its promoters, or any affiliated entity for the preparation of this report. The analysis reflects the author's independent opinion based on publicly available information and accepted valuation methodologies. The author may or may not hold securities discussed in this report, and any such holdings, if applicable, do not influence the conclusions presented herein.